Stocks got off to a slightly lower start Tuesday as investors digested a stream of earnings reports, including results from Dow components Johnson & Johnson JNJ, -0.84% and Goldman Sachs Group Inc. GS, +2.42% The Dow Jones Industrial Average DJIA, +0.07% fell around 7 points, or less than 0.
1%, to 27,352, while the S&P 500 SPX, -0.03% was off 0.1% at 3,011.12. The Nasdaq Composite COMP, -0.08% fell 0.1% to 8,245.28. All three major indexes eked out record finished in subdued trading on Monday. Shares of Goldman Sachs were up 0.9%, while Johnson & Johnson shares fell 1.7%. Both companies topped earnings forecasts.
Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше:
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
World stocks mark time ahead of U.S. data, earningsGlobal stocks struggled to cling to recent gains on Tuesday and the dollar linge...
Источник: Reuters - 🏆 2. / 97 Прочитайте больше »
European stocks set to open higher despite China slowdown fearsEuropean stocks are set to rise Monday, despite worries China's economy is slowing amid a trade war with the U.S.
Источник: CNBC - 🏆 12. / 72 Прочитайте больше »
U.S. stocks set to tread water as investors await trio of bank earningsU.S. stock futures trade on either side of unchanged Tuesday morning a day after major equity indexes eked out a round of fresh all-time closing highs as Wall Street braces for a trifecta of bank earnings — likely to set the tone for trading on the day.
Источник: MarketWatch - 🏆 3. / 97 Прочитайте больше »
European stocks seen under pressure as investors await earningsEuropean stocks are set to begin Tuesday's session mixed as traders monitor a slew of earnings reports.
Источник: CNBC - 🏆 12. / 72 Прочитайте больше »
Cannabis stocks rally after FDA says it will speed up effort to create rules for CBDCannabis stocks were mostly higher on Monday, after the U.S. Food and Drug Administration said it is expediting its effort to create a regulatory framework... Interesting to watch. How much of this is a hype? Is everything already priced in and the current rally is purely based on the future/speculation?
Источник: MarketWatch - 🏆 3. / 97 Прочитайте больше »